Skip to content
Browse
LatestWorldBusinessSci & TechEntertainmentSportsHealthGames

Edition

GLGlobalUSUSACACanadaUKUKINIndiaPKPakistanSGSingaporeAUAustralia

Sections

Appearance

AboutSourcesContactPrivacy

iX Biopharma replies SGX queries on partner’s licence, says US$41m Pentagon ketamine wafer deal unaffected

Its stock rose more than 1% on Nov 4 after responding to SGX, and has more than tripled year-to-date.

First reported by The Straits Times 1 source
Read at The Straits Times(opens in a new tab)

Full coverage

Every report we found on this story, oldest first. Each links to the original publisher.

  1. The Straits Times

    iX Biopharma replies SGX queries on partner’s licence, says US$41m Pentagon ketamine wafer deal unaffected (opens The Straits Times in a new tab)

    Its stock rose more than 1% on Nov 4 after responding to SGX, and has more than tripled year-to-date.

Something wrong with how we've grouped or summarised this story? Report a problem

More in Business

More